Sandbox:Amrit: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Created page with "__NOTOC__ {{CMG}}; {{AE}} {{Amrit Kaur}} Practice here. <ref name="pmid27261907">{{cite journal| author=Mao Y, Yang D, He J, Krasna MJ| title=Epidemiology of Lung Cancer...."
 
No edit summary
 
Line 12: Line 12:


{|  
{|  
|+'''Classification of Waldenstrom macroglobulinemia (WM) and Related Disorders'''
|+'''Stages of Chronic Kidney disease'''
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Criteria
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Stages
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptomatic WM
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Description
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Asymptomatic WM
! style="background:#4479BA; color: #FFFFFF;" align="center" + |GFR
! style="background:#4479BA; color: #FFFFFF;" align="center" + |IgM-Related Disorders
! style="background:#4479BA; color: #FFFFFF;" align="center" + |MGUS
|-
|-
! align="center" style="background:#DCDCDC;" + |IgM monoclonal protein
! align="center" style="background:#DCDCDC;" + |Stage I
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | Kidney damage with normal or increased GFR
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | >90
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
|-
|-
! align="center" style="background:#DCDCDC;" + |Bone marrow infiltration
! align="center" style="background:#DCDCDC;" + |Stage II
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | kidney damage with mild decrease in GFR
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | 60-89
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | -
|-
|-
! align="center" style="background:#DCDCDC;" + |Symptoms attributable to IgM
! align="center" style="background:#DCDCDC;" + |Stage III
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | Moderate decrease in GFR
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | 30-59
| style="background:#F5F5F5;" align="center" + | +
|-
| style="background:#F5F5F5;" align="center" + | -
! align="center" style="background:#DCDCDC;" + |Stage IV
| style="background:#F5F5F5;" align="center" + | Severe decrease in GFR
| style="background:#F5F5F5;" align="center" + | 15-29
|-
! align="center" style="background:#DCDCDC;" + |Stage V
| style="background:#F5F5F5;" align="center" + | Kidney failure
| style="background:#F5F5F5;" align="center" + | <15
|-
|-
! align="center" style="background:#DCDCDC;" + |Symptoms attributable to tumor infiltration
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | -
|}<br />
|}<br />


Latest revision as of 02:54, 18 January 2021


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amrit Kaur, M.B.B.S.[2]


Practice here.

[1]

High-power field of peripheral blood smear revealing a large, atypical B cell with mild cytoplasmic expansion, coarse chromatin, multiple distinct nucleoli and peripheral vacuolation.Source: Charakidis M. et al, Department of Haematology-Oncology, Royal Hobart Hospital, Tasmania, 7000, Australia.


Stages of Chronic Kidney disease
Stages Description GFR
Stage I Kidney damage with normal or increased GFR >90
Stage II kidney damage with mild decrease in GFR 60-89
Stage III Moderate decrease in GFR 30-59
Stage IV Severe decrease in GFR 15-29
Stage V Kidney failure <15


Libman-Sacks endocarditis Microchapters

Overview

Historical Perspective

Pathophysiology

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Imaging Findings

Other Diagnostic Studies

Treatment

Differentiating Libman-Sacks Endocarditis from other Diseases



Reference

  1. ↑ Mao Y, Yang D, He J, Krasna MJ (2016). "Epidemiology of Lung Cancer". Surg Oncol Clin N Am. 25 (3): 439–45. doi:10.1016/j.soc.2016.02.001. PMID 27261907.
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox:Amrit&oldid=1683563"